Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPHCDL)

Drug Name
GLPG-0634 Drug Info
Synonyms Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 2 [1]
Cutaneous lupus erythematosus EB5Z Phase 2 [2]
Rheumatoid arthritis FA20 Phase 2 [3]
Cross-matching ID
PubChem CID
49831257
CAS Number
CAS 1206161-97-8
TTD Drug ID
DMPHCDL

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Janus kinase 1 (JAK-1) DTT JAK1 8.621 9.012 9.168 8.535
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Crohn disease
ICD Disease Classification DD70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Janus kinase 1 (JAK-1) DTT JAK1 2.16E-02 -0.21 -0.36
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7913).
4 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.